Fbw7 and its counteracting forces in stem cells and cancer: Oncoproteins in the balance

Seminars in Cancer Biology

Volumn 36, Issue , 2016, Pages 52-61

  Cremona, Catherine A ^a   Sancho, Rocio ^a   Diefenbacher, Markus E ^a,c,d   Behrens, Axel ^a,b  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cancer; DUB; Fbw7; Ubiquitin; USP28

Indexed keywords

FBW7 PROTEIN; ONCOPROTEIN; REGULATOR PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; USP36 PROTEIN; CELL CYCLE PROTEIN; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; PROTEASOME; PROTEIN BINDING; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; CANCER STEM CELL; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; FBW7 GENE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; INTESTINE; LIVER PARENCHYMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR RECOGNITION; MULTIPLE MYELOMA; NEURAL STEM CELL; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN TARGETING; REGULATOR GENE; REVIEW; TUMOR INVASION; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CYTOLOGY; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL PROLIFERATION; F-BOX PROTEINS; HUMANS; NEOPLASMS; ONCOGENE PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; SIGNAL TRANSDUCTION; STEM CELLS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84958114871     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.09.006     Document Type: Review

References (97)

1. Welcker M., Clurman B.E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 2008, 8(2):83-93. PubMed PMID: 18094723. 10.1038/nrc2290.
2. Oberg C., Li J., Pauley A., Wolf E., Gurney M., Lendahl U. The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J. Biol. Chem. 2001, 276(38):35847-35853. PubMed PMID: 11461910. 10.1074/jbc.M103992200.
3. Strohmaier H., Spruck C.H., Kaiser P., Won K.A., Sangfelt O., Reed S.I. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001, 413(6853):316-322. PubMed PMID: 11565034. 10.1038/35095076.
4. Welcker M., Orian A., Jin J., Grim J.E., Harper J.W., Eisenman R.N., et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(24):9085-9090. PubMed PMID: 15150404; PubMed Central PMCID: PMC428477. 10.1073/pnas.0402770101.
5. Finkin S., Aylon Y., Anzi S., Oren M., Shaulian E. Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy. Oncogene 2008, 27(32):4411-4421. PubMed PMID: 18391985. 10.1038/onc.2008.77.
6. Kanei-Ishii C., Nomura T., Takagi T., Watanabe N., Nakayama K.I., Ishii S. Fbxw7 acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase (NLK)-induced degradation. J. Biol. Chem. 2008, 283(45):30540-30548. PubMed PMID: 18765672; PubMed Central PMCID: PMC2662147. 10.1074/jbc.M804340200.
7. Zhao D., Zheng H.Q., Zhou Z., Chen C. The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res. 2010, 70(11):4728-4738. PubMed PMID: 20484041. 10.1158/0008-5472.CAN-10-0040.
8. Inuzuka H., Shaik S., Onoyama I., Gao D., Tseng A., Maser R.S., et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011, 471(7336):104-109. PubMed PMID: 21368833; PubMed Central PMCID: PMC3076007. 10.1038/nature09732.
9. Mao J.H., Kim I.J., Wu D., Climent J., Kang H.C., DelRosario R., et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008, 321(5895):1499-1502. PubMed PMID: 18787170; PubMed Central PMCID: PMC2849753. 10.1126/science.1162981.
10. Rocher-Ros V., Marco S., Mao J.H., Gines S., Metzger D., Chambon P., et al. Presenilin modulates EGFR signaling and cell transformation by regulating the ubiquitin ligase Fbw7. Oncogene 2010, 29(20):2950-2961. PubMed PMID: 20208556; PubMed Central PMCID: PMC4162408. 10.1038/onc.2010.57.
11. Sundqvist A., Bengoechea-Alonso M.T., Ye X., Lukiyanchuk V., Jin J., Harper J.W., et al. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab. 2005, 1(6):379-391. PubMed PMID: 16054087. 10.1016/j.cmet.2005.04.010.
12. Flugel D., Gorlach A., Kietzmann T. GSK-3beta regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1alpha. Blood 2012, 119(5):1292-1301. PubMed PMID: 22144179; PubMed Central PMCID: PMC3352078. 10.1182/blood-2011-08-375014.
13. Davis R.J., Welcker M., Clurman B.E. Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell 2014, 26(4):455-464. PubMed PMID: 25314076; PubMed Central PMCID: PMC4227608. 10.1016/j.ccell.2014.09.013.
14. Cohen P., Tcherpakov M. Will the ubiquitin system furnish as many drug targets as protein kinases?. Cell 2010, 143(5):686-693. PubMed PMID: 21111230. 10.1016/j.cell.2010.11.016.
15. Micel L.N., Tentler J.J., Smith P.G., Eckhardt G.S. Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2013, 31(9):1231-1238. PubMed PMID: 23358974; PubMed Central PMCID: PMC3807137. 10.1200/JCO.2012.44.0958.
16. Kubiczkova L., Pour L., Sedlarikova L., Hajek R., Sevcikova S. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J. Cell. Mol. Med. 2014, 18(6):947-961. PubMed PMID: 24712303. 10.1111/jcmm.12279.
17. Skaar J.R., Pagan J.K., Pagano M. SCF ubiquitin ligase-targeted therapies. Nat. Rev. Drug Discov. 2014, 13(12):889-903. PubMed PMID: 25394868; PubMed Central PMCID: PMC4410837. 10.1038/nrd4432.
18. Bulatov E., Ciulli A. Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation. Biochem. J. 2015, 467(3):365-386. PubMed PMID: 25886174; PubMed Central PMCID: PMC4403949. 10.1042/BJ20141450.
19. Wang Z., Liu P., Inuzuka H., Wei W. Roles of F-box proteins in cancer. Nat. Rev. Cancer 2014, 14(4):233-247. PubMed PMID: 24658274; PubMed Central PMCID: PMC4306233. 10.1038/nrc3700.
20. Wang Z., Inuzuka H., Fukushima H., Wan L., Gao D., Shaik S., et al. Emerging roles of the FBW7 tumour suppressor in stem cell differentiation. EMBO Rep. 2012, 13(1):36-43. PubMed PMID: 22157894; PubMed Central PMCID: PMC3246256. 10.1038/embor.2011.231.
21. Barker N., Ridgway R.A., van Es J.H., van de Wetering M., Begthel H., van den Born M., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457(7229):608-611. PubMed PMID: 19092804. 10.1038/nature07602.
22. Hoeck J.D., Jandke A., Blake S.M., Nye E., Spencer-Dene B., Brandner S., et al. Fbw7 controls neural stem cell differentiation and progenitor apoptosis via Notch and c-Jun. Nat. Neurosci. 2010, 13(11):1365-1372. PubMed PMID: 20935640. 10.1038/nn.2644.
23. Jandke A., Da Costa C., Sancho R., Nye E., Spencer-Dene B., Behrens A. The F-box protein Fbw7 is required for cerebellar development. Dev. Biol. 2011, 358(1):201-212. PubMed PMID: 21827743. 10.1016/j.ydbio.2011.07.030.
24. Sancho R., Jandke A., Davis H., Diefenbacher M.E., Tomlinson I., Behrens A. F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor. Gastroenterology 2010, 139(3):929-941. PubMed PMID: 20638938. 10.1053/j.gastro.2010.05.078.
25. Thompson B.J., Jankovic V., Gao J., Buonamici S., Vest A., Lee J.M., et al. Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J. Exp. Med. 2008, 205(6):1395-1408. PubMed PMID: 18474632; PubMed Central PMCID: PMC2413036. 10.1084/jem.20080277.
26. Matsuoka S., Oike Y., Onoyama I., Iwama A., Arai F., Takubo K., et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev. 2008, 22(8):986-991. PubMed PMID: 18367647; PubMed Central PMCID: PMC2335330. 10.1101/gad.1621808.
27. Onoyama I., Suzuki A., Matsumoto A., Tomita K., Katagiri H., Oike Y., et al. Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver. J. Clin. Investig. 2011, 121(1):342-354. PubMed PMID: 21123947; PubMed Central PMCID: PMC3007132. 10.1172/JCI40725.
28. Matsumoto A., Onoyama I., Sunabori T., Kageyama R., Okano H., Nakayama K.I. Fbxw7-dependent degradation of Notch is required for control of "stemness" and neuronal-glial differentiation in neural stem cells. J. Biol. Chem. 2011, 286(15):13754-13764. PubMed PMID: 21349854; PubMed Central PMCID: PMC3075719. 10.1074/jbc.M110.194936.
29. Sancho R., Blake S.M., Tendeng C., Clurman B.E., Lewis J., Behrens A. Fbw7 repression by hes5 creates a feedback loop that modulates Notch-mediated intestinal and neural stem cell fate decisions. PLoS Biol. 2013, 11(6):e1001586. PubMed PMID: 23776410; PubMed Central PMCID: PMC3679002. 10.1371/journal.pbio.1001586.
30. Iriuchishima H., Takubo K., Matsuoka S., Onoyama I., Nakayama K.I., Nojima Y., et al. Ex vivo maintenance of hematopoietic stem cells by quiescence induction through Fbxw7α overexpression. Blood 2011, 117(8):2373-2377. PubMed PMID: 21190997. 10.1182/blood-2010-07-294801.
31. Reavie L., Della Gatta G., Crusio K., Aranda-Orgilles B., Buckley S.M., Thompson B., et al. Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligase-substrate complex. Nat. Immunol. 2010, 11(3):207-215. PubMed PMID: 20081848; PubMed Central PMCID: PMC2825759. 10.1038/ni.1839.
32. Kanatsu-Shinohara M., Onoyama I., Nakayama K.I., Shinohara T. Skp1-Cullin-F-box (SCF)-type ubiquitin ligase FBXW7 negatively regulates spermatogonial stem cell self-renewal. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(24):8826-8831. PubMed PMID: 24879440; PubMed Central PMCID: PMC4066470. 10.1073/pnas.1401837111.
33. Sancho R., Gruber R., Gu G., Behrens A. Loss of Fbw7 reprograms adult pancreatic ductal cells into alpha, delta, and beta cells. Cell Stem Cell 2014, 15(2):139-153. PubMed PMID: 25105579; PubMed Central PMCID: PMC4136739. 10.1016/j.stem.2014.06.019.
34. Moberg K.H., Bell D.W., Wahrer D.C., Haber D.A., Hariharan I.K. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 2001, 413(6853):311-316. PubMed PMID: 11565033. 10.1038/35095068.
35. Koepp D.M., Schaefer L.K., Ye X., Keyomarsi K., Chu C., Harper J.W., et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001, 294(5540):173-177. PubMed PMID: 11533444. 10.1126/science.1065203.
36. Wu G., Lyapina S., Das I., Li J., Gurney M., Pauley A., et al. SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. Mol. Cell. Biol. 2001, 21(21):7403-7415. PubMed PMID: 11585921; PubMed Central PMCID: PMC99913. 10.1128/MCB.21.21.7403-7415.2001.
37. Gupta-Rossi N., Le Bail O., Gonen H., Brou C., Logeat F., Six E., et al. Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. J. Biol. Chem. 2001, 276(37):34371-34378. PubMed PMID: 11425854. 10.1074/jbc.M101343200.
38. Spruck C.H., Strohmaier H., Sangfelt O., Muller H.M., Hubalek M., Muller-Holzner E., et al. hCDC4 gene mutations in endometrial cancer. Cancer Res. 2002, 62(16):4535-4539. PubMed PMID: 12183400.
39. Calhoun E.S., Jones J.B., Ashfaq R., Adsay V., Baker S.J., Valentine V., et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am. J. Pathol. 2003, 163(4):1255-1260. PubMed PMID: 14507635; PubMed Central PMCID: PMC1868306. 10.1016/S0002-9440(10)63485-2.
40. Nateri A.S., Riera-Sans L., Da Costa C., Behrens A. The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science 2004, 303(5662):1374-1378. PubMed PMID: 14739463. 10.1126/science.1092880.
41. Mao J.H., Perez-Losada J., Wu D., Delrosario R., Tsunematsu R., Nakayama K.I., et al. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 2004, 432(7018):775-779. PubMed PMID: 15592418. 10.1038/nature03155.
42. Akhoondi S., Sun D., von der Lehr N., Apostolidou S., Klotz K., Maljukova A., et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007, 67(19):9006-9012. PubMed PMID: 17909001. 10.1158/0008-5472.CAN-07-1320.
43. Knuutila S., Aalto Y., Autio K., Bjorkqvist A.M., El-Rifai W., Hemmer S., et al. DNA copy number losses in human neoplasms. Am J. Pathol. 1999, 155(3):683-694. PubMed PMID: 10487825; PubMed Central PMCID: PMC1866903. 10.1016/S0002-9440(10)65166-8.
44. Wrage M., Ruosaari S., Eijk P.P., Kaifi J.T., Hollmen J., Yekebas E.F., et al. Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2009, 15(5):1566-1574. PubMed PMID: 19208797. 10.1158/1078-0432.CCR-08-2188.
45. Ji S., Qin Y., Shi S., Liu X., Hu H., Zhou H., et al. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res. 2015, 25(5):561-573. PubMed PMID: 25753158; PubMed Central PMCID: PMC4423074. 10.1038/cr.2015.30.
46. Wang Z., Inuzuka H., Zhong J., Wan L., Fukushima H., Sarkar F.H., et al. Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett. 2012, 586(10):1409-1418. PubMed PMID: 22673505; PubMed Central PMCID: PMC3372850. 10.1016/j.febslet.2012.03.017.
47. King B., Trimarchi T., Reavie L., Xu L., Mullenders J., Ntziachristos P., et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 2013, 153(7):1552-1566. PubMed PMID: 23791182; PubMed Central PMCID: PMC4146439. 10.1016/j.cell.2013.05.041.
48. Kwon Y.W., Kim I.J., Wu D., Lu J., Stock W.A., Liu Y., et al. Pten regulates Aurora-and cooperates with Fbxw7 in modulating radiation-induced tumor development. Mol. Cancer Res.: MCR 2012, 10(6):834-844. PubMed PMID: 22513362; PubMed Central PMCID: PMC3388112. 10.1158/1541-7786.MCR-12-0025.
49. Onoyama I., Tsunematsu R., Matsumoto A., Kimura T., de Alboran I.M., Nakayama K., et al. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J. Exp. Med. 2007, 204(12):2875-2888. PubMed PMID: 17984302; PubMed Central PMCID: PMC2118521. 10.1084/jem.20062299.
50. O'Neil J., Grim J., Strack P., Rao S., Tibbitts D., Winter C., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 2007, 204(8):1813-1824. PubMed PMID: 17646409; PubMed Central PMCID: PMC2118656. 10.1084/jem.20070876.
51. Youle R.J., Strasser A. The BCL-protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9(1):47-59. PubMed PMID: 18097445. 10.1038/nrm2308.
52. Lau A.W., Fukushima H., Wei W. The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front. Biosci. 2012, 17:2197-2212. PubMed PMID: 22652772; PubMed Central PMCID: PMC3374336.
53. Wertz I.E., Kusam S., Lam C., Okamoto T., Sandoval W., Anderson D.J., et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011, 471(7336):110-114. PubMed PMID: 21368834. 10.1038/nature09779.
54. Koo J., Yue P., Deng X., Khuri F.R., Sun S.Y. mTOR complex 2 stabilizes Mcl-protein by suppressing its glycogen synthase kinase 3-dependent and SCF-FBXW7-mediated degradation. Mol. Cell. Biol. 2015, 35(13):2344-2355. PubMed PMID: 25918246; PubMed Central PMCID: PMC4456440. 10.1128/MCB.01525-14.
55. Rajagopalan H., Jallepalli P.V., Rago C., Velculescu V.E., Kinzler K.W., Vogelstein B., et al. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004, 428(6978):77-81. PubMed PMID: 14999283. 10.1038/nature02313.
56. Davis H., Lewis A., Behrens A., Tomlinson I. Investigation of the atypical FBXW7 mutation spectrum in human tumours by conditional expression of a heterozygous propellor tip missense allele in the mouse intestines. Gut 2014, 63(5):792-799. PubMed PMID: 23676439; PubMed Central PMCID: PMC3995284. 10.1136/gutjnl-2013-304719.
57. Babaei-Jadidi R., Li N., Saadeddin A., Spencer-Dene B., Jandke A., Muhammad B., et al. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J. Exp. Med. 2011, 208(2):295-312. PubMed PMID: 21282377; PubMed Central PMCID: PMC3039859. 10.1084/jem.20100830.
58. Sansom O.J., Meniel V.S., Muncan V., Phesse T.J., Wilkins J.A., Reed K.R., et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007, 446(7136):676-679. PubMed PMID: 17377531. 10.1038/nature05674.
59. Fang L., Yang Z., Zhou J., Tung J.Y., Hsiao C.D., Wang L., et al. Circadian clock gene CRY2 degradation is involved in chemoresistance of colorectal cancer. Mol. Cancer Ther. 2015, 14(6):1476-1487. PubMed PMID: 25855785; PubMed Central PMCID: PMC4458447. 10.1158/1535-7163.MCT-15-0030.
60. Tu K., Yang W., Li C., Zheng X., Lu Z., Guo C., et al. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol. Cancer 2014, 13:110. PubMed PMID: 24884509; PubMed Central PMCID: PMC4035898. 10.1186/1476-4598-13-110.
61. Giraldez S., Herrero-Ruiz J., Mora-Santos M., Japon M.A., Tortolero M., Romero F. SCF(FBXW7alpha) modulates the intra-S-phase DNA-damage checkpoint by regulating Polo like kinase-stability. Oncotarget 2014, 5(12):4370-4383. PubMed PMID: 24970797; PubMed Central PMCID: PMC4147330.
62. Kourtis N., Moubarak R.S., Aranda-Orgilles B., Lui K., Aydin I.T., Trimarchi T., et al. FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. Nat. Cell Biol. 2015, 17(3):322-332. PubMed PMID: 25720964; PubMed Central PMCID: PMC4401662. 10.1038/ncb3121.
63. Wang X., Zhang J., Zhou L., Sun W., Zheng Z.G., Lu P., et al. Fbxw7 regulates hepatocellular carcinoma migration and invasion via Notch1 signaling pathway. Int. J. Oncol. 2015, 47(1):231-243. PubMed PMID: 25955618. 10.3892/ijo.2015.2981.
64. Yumimoto K., Akiyoshi S., Ueo H., Sagara Y., Onoyama I., Ueo H., et al. F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner. J. Clin. Investig. 2015, 125(2):621-635. PubMed PMID: 25555218; PubMed Central PMCID: PMC4319427. 10.1172/JCI78782.
65. Tsunematsu R., Nakayama K., Oike Y., Nishiyama M., Ishida N., Hatakeyama S., et al. Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J. Biol. Chem. 2004, 279(10):9417-9423. PubMed PMID: 14672936. 10.1074/jbc.M312337200.
66. Takeishi S., Matsumoto A., Onoyama I., Naka K., Hirao A., Nakayama K.I. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 2013, 23(3):347-361. PubMed PMID: 23518349. 10.1016/j.ccr.2013.01.026.
67. Reavie L., Buckley S.M., Loizou E., Takeishi S., Aranda-Orgilles B., Ndiaye-Lobry D., et al. Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell 2013, 23(3):362-375. PubMed PMID: 23518350; PubMed Central PMCID: PMC3609428. 10.1016/j.ccr.2013.01.025.
68. Olive V., Sabio E., Bennett M.J., De Jong C.S., Biton A., McGann J.C., et al. A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis. eLife 2013, 2:e00822. PubMed PMID: 24137534; PubMed Central PMCID: PMC3796314. 10.7554/eLife.00822.
69. Asnafi V., Buzyn A., Le Noir S., Baleydier F., Simon A., Beldjord K., et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009, 113(17):3918-3924. PubMed PMID: 19109228. 10.1182/blood-2008-10-184069.
70. Akhoondi S., Lindstrom L., Widschwendter M., Corcoran M., Bergh J., Spruck C., et al. Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res.: BCR 2010, 12(6):R105. PubMed PMID: 21122106; PubMed Central PMCID: PMC3046450. 10.1186/bcr2788.
71. Busino L., Millman S.E., Scotto L., Kyratsous C.A., Basrur V., O'Connor O., et al. Fbxw7alpha- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat. Cell Biol. 2012, 14(4):375-385. PubMed PMID: 22388891; PubMed Central PMCID: PMC3339029. 10.1038/ncb2463.
72. Busino L., Millman S.E., Pagano M. SCF-mediated degradation of p100 (NF-kappaB2): mechanisms and relevance in multiple myeloma. Sci. Signal. 2012, 5(253). pt14. PubMed PMID: 23211527; PubMed Central PMCID: PMC3871187. 10.1126/scisignal.2003408.
73. Wang L., Ye X., Liu Y., Wei W., Wang Z. Aberrant regulation of FBW7 in cancer. Oncotarget 2014, 5(8):2000-2015. PubMed PMID: 24899581; PubMed Central PMCID: PMC4039140.
74. Kimura T., Gotoh M., Nakamura Y., Arakawa H. hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci. 2003, 94(5):431-436. PubMed PMID: 12824889.
75. Lu D., Davis M.P., Abreu-Goodger C., Wang W., Campos L.S., Siede J., et al. MiR-25 regulates Wwp2 and Fbxw7 and promotes reprogramming of mouse fibroblast cells to iPSCs. PLOS ONE 2012, 7(8):e40938. PubMed PMID: 22912667; PubMed Central PMCID: PMC3422229. 10.1371/journal.pone.0040938.
76. Lerner M., Lundgren J., Akhoondi S., Jahn A., Ng H.F., Akbari Moqadam F., et al. MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle 2011, 10(13):2172-2183. PubMed PMID: 21597324.
77. Xu Y., Sengupta T., Kukreja L., Minella A.C. MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7. J. Biol. Chem. 2010, 285(45):34439-34446. PubMed PMID: 20826802; PubMed Central PMCID: PMC2966058. 10.1074/jbc.M110.152306.
78. Kurashige J., Watanabe M., Iwatsuki M., Kinoshita K., Saito S., Hiyoshi Y., et al. Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. Br. J. Cancer 2012, 106(1):182-188. PubMed PMID: 22108521; PubMed Central PMCID: PMC3251856. 10.1038/bjc.2011.509.
79. Li L., Sarver A.L., Khatri R., Hajeri P.B., Kamenev I., French A.J., et al. Sequential expression of miR-182 and miR-503 cooperatively targets FBXW7, contributing to the malignant transformation of colon adenoma to adenocarcinoma. J. Pathol. 2014, 234(4):488-501. PubMed PMID: 25269767. 10.1002/path.4407.
80. Wang Q., Li D.C., Li Z.F., Liu C.X., Xiao Y.M., Zhang B., et al. Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen. Oncogene 2011, 30(36):3875-3886. PubMed PMID: 21460851. 10.1038/onc.2011.103.
81. Jahid S., Sun J., Edwards R.A., Dizon D., Panarelli N.C., Milsom J.W., et al. miR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov. 2012, 2(6):540-553. PubMed PMID: 22628407; PubMed Central PMCID: PMC3651884. 10.1158/2159-8290.CD-11-0267.
82. Ekholm-Reed S., Goldberg M.S., Schlossmacher M.G., Reed S.I. Parkin-dependent degradation of the F-box protein Fbw7beta promotes neuronal survival in response to oxidative stress by stabilizing Mcl-1. Mol. Cell. Biol. 2013, 33(18):3627-3643. PubMed PMID: 23858059; PubMed Central PMCID: PMC3753862. 10.1128/MCB.00535-13.
83. Schulein C., Eilers M., Popov N. PI3K-dependent phosphorylation of Fbw7 modulates substrate degradation and activity. FEBS Lett. 2011, 585(14):2151-2157. PubMed PMID: 21620836. 10.1016/j.febslet.2011.05.036.
84. Min S.H., Lau A.W., Lee T.H., Inuzuka H., Wei S., Huang P., et al. Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. Mol. Cell 2012, 46(6):771-783. PubMed PMID: 22608923; PubMed Central PMCID: PMC3389221. 10.1016/j.molcel.2012.04.012.
85. Welcker M., Larimore E.A., Swanger J., Bengoechea-Alonso M.T., Grim J.E., Ericsson J., et al. Fbw7 dimerization determines the specificity and robustness of substrate degradation. Genes Dev. 2013, 27(23):2531-2536. PubMed PMID: 24298052; PubMed Central PMCID: PMC3861666. 10.1101/gad.229195.113.
86. Komander D., Clague M.J., Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat. Rev. Mol. Cell Biol. 2009, 10(8):550-563. PubMed PMID: 19626045. 10.1038/nrm2731.
87. Li M., Chen D., Shiloh A., Luo J., Nikolaev A.Y., Qin J., et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002, 416(6881):648-653. PubMed PMID: 11923872. 10.1038/nature737.
88. Ahmed N., Zeng M., Sinha I., Polin L., Wei W.Z., Rathinam C., et al. The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat. Immunol. 2011, 12(12):1176-1183. PubMed PMID: 22057290; PubMed Central PMCID: PMC3219826. 10.1038/ni.2157.
89. Popov N., Wanzel M., Madiredjo M., Zhang D., Beijersbergen R., Bernards R., et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat. Cell Biol. 2007, 9(7):765-774. PubMed PMID: 17558397. 10.1038/ncb1601.
90. Diefenbacher M.E., Popov N., Blake S.M., Schulein-Volk C., Nye E., Spencer-Dene B., et al. The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer. J. Clin. Investig. 2014, 124(8):3407-3418. PubMed PMID: 24960159; PubMed Central PMCID: PMC4109555. 10.1172/JCI73733.
91. Diefenbacher M.E., Chakraborty A., Blake S.M., Mitter R., Popov N., Eilers M., et al. Usp28 counteracts Fbw7 in intestinal homeostasis and cancer. Cancer Res. 2015, 75(7):1181-1186. PubMed PMID: 25716680; PubMed Central PMCID: PMC4384988. 10.1158/0008-5472.CAN-14-1726.
92. Zhang D., Zaugg K., Mak T.W., Elledge S.J. A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell 2006, 126(3):529-542. PubMed PMID: 16901786. 10.1016/j.cell.2006.06.039.
93. Bohgaki M., Hakem A., Halaby M.J., Bohgaki T., Li Q., Bissey P.A., et al. The E3 ligase PIRH2 polyubiquitylates CHK2 and regulates its turnover. Cell Death Differ. 2013, 20(6):812-822. PubMed PMID: 23449389; PubMed Central PMCID: PMC3647240. 10.1038/cdd.2013.7.
94. Wu Y., Wang Y., Yang X.H., Kang T., Zhao Y., Wang C., et al. The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells. Cell Rep. 2013, 5(1):224-236. PubMed PMID: 24075993; PubMed Central PMCID: PMC4004762. 10.1016/j.celrep.2013.08.030.
95. Schulein-Volk C., Wolf E., Zhu J., Xu W., Taranets L., Hellmann A., et al. Dual regulation of Fbw7 function and oncogenic transformation by Usp28. Cell Rep. 2014, 9(3):1099-1109. PubMed PMID: 25437563. 10.1016/j.celrep.2014.09.057.
96. Forbes S.A., Beare D., Gunasekaran P., Leung K., Bindal N., Boutselakis H., et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015, 43(Database issue):D805-D811. PubMed PMID: 25355519; PubMed Central PMCID: PMC4383913. 10.1093/nar/gku1075.
97. Sun X.X., He X., Yin L., Komada M., Sears R.C., Dai M.S. The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc. Proc. Natl. Acad. Sci. U. S. A. 2015, 112(12):3734-3739. PubMed PMID: 25775507; PubMed Central PMCID: PMC4378440. 10.1073/pnas.1411713112.